Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

30.89
+0.21000.68%
Post-market: 30.80-0.0900-0.29%19:59 EDT
Volume:1.22M
Turnover:37.49M
Market Cap:3.57B
PE:-7.43
High:30.92
Open:30.58
Low:30.29
Close:30.68
52wk High:43.15
52wk Low:22.96
Shares:115.55M
Float Shares:110.00M
Volume Ratio:0.58
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1600
EPS(LYR):-3.1920
ROE:-70.04%
ROA:-42.54%
PB:7.11
PE(LYR):-9.68

Loading ...

Company Profile

Company Name:
Viking Therapeutics
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
59
Office Location:
9920 Pacific Heights Boulevard,Suite 350,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Directors

Name
Position
Brian Lian
President and Chief Executive Officer, Director
Charles A. Rowland, Jr.
Independent Director
J. Matthew Singleton
Independent Director
Lawson Macartney
Chairperson and Director
S. Kathryn Rouan
Independent Director
Matthew W. Foehr
Director

Shareholders

Name
Position
Brian Lian
President and Chief Executive Officer, Director
Marianne Mancini
Chief Operating Officer
Greg Zante
Chief Financial Officer
Neil Aubuchon
Chief Commercial Officer